GYKI-16084

• CAT Number: I007172
• CAS Number: 185739-21-3 (free base)
• Molecular Formula: C16H19N3O3
• Molecular Weight: 301.35
• Purity: ≥95%
• Synonyms: GYKI-16084; GYKI 16084; GYKI16084.;(R)-2-(3-(((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)amino)propyl)pyridazin-3(2H)-one
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term , or -20°C for long term.
• IUPAC Name: 2-[3-[[(3R)-2,3-dihydro-1,4-benzodioxin-3-yl]methylamino]propyl]pyridazin-3-one
• InChI: InChI=1S/C16H19N3O3/c20-16-7-3-9-18-19(16)10-4-8-17-11-13-12-21-14-5-1-2-6-15(14)22-13/h1-3,5-7,9,13,17H,4,8,10-12H2/t13-/m1/s1
• InChIKey: FJNRJBQUOQLUNQ-CYBMUJFWSA-N
• SMILES: C1[C@H](OC2=CC=CC=C2O1)CNCCCN3C(=O)C=CC=N3

GYKI-16084（Cat No.:I007172）is a selective antagonist of the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor, a subtype of glutamate receptors involved in excitatory neurotransmission in the brain. By inhibiting AMPA receptor activity, GYKI-16084 modulates glutamatergic signaling, which is implicated in various neurological processes such as learning, memory, and synaptic plasticity. The compound has been studied for its potential in treating conditions associated with excessive glutamate activity, including epilepsy, neurodegenerative diseases, and ischemic stroke. Preclinical research indicates GYKI-16084’s promise, though further studies are necessary to evaluate its safety and therapeutic potential in humans.